Phathom Pharmaceuticals (PHAT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	337.54 mm	337.54 mm	337.54 mm	337.54 mm	337.54 mm	337.54 mm
Cash burn (monthly)	(no burn)	(no burn)	23.60 mm	23.99 mm	21.19 mm	20.59 mm
Cash used (since last report)	n/a	n/a	100.51 mm	102.19 mm	90.25 mm	87.70 mm
Cash remaining	n/a	n/a	237.03 mm	235.35 mm	247.29 mm	249.84 mm
Runway (months of cash)	n/a	n/a	10.0	9.8	11.7	12.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PHAT institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	137	118	+16.1%
Opened positions	29	22	+31.8%
Closed positions	10	18	-44.4%
Increased positions	57	47	+21.3%
Reduced positions	18	19	-5.3%

13F shares	Current	Prev Q	Change
Total value	1.29 tn	575.39 bn	+123.8%
Total shares	95.51 mm	79.43 mm	+20.2%
Total puts	45.70 k	34.90 k	+30.9%
Total calls	41.00 k	465.40 k	-91.2%
Total put/call ratio	1.1	0.1	+1386.4%

Largest owners	Shares	Value	Change
Frazier Life Sciences Management	10.11 mm	$182.78 bn	0.0%
Medicxi Growth I	7.46 mm	$79.12 mm	0.0%
Medicxi Ventures Management	7.46 mm	$134.96 bn	0.0%
Jennison Associates	5.87 mm	$106.06 bn	+112.7%
Frazier Life Sciences IX	5.83 mm	$58.39 mm	0.0%
Frazier Life Sciences Public Fund	5.83 mm	$74.65 mm	0.0%
IVZ Invesco	4.10 mm	$74.07 bn	+30.3%
TAK Takeda Pharmaceutical Company Limited	3.76 mm	$0.00	0.0%
CG The Carlyle Group Inc.	3.50 mm	$63.19 bn	0.0%
BlackRock	3.12 mm	$56.46 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BlackRock	3.12 mm	+3.12 mm	NEW
Jennison Associates	5.87 mm	+3.11 mm	+112.7%
BLK BlackRock	0.00	-2.93 mm	EXIT
Woodline Partners	2.57 mm	+1.79 mm	+227.4%
Orbimed Advisors	1.45 mm	+1.45 mm	NEW
FHI Federated Hermes	1.40 mm	+1.40 mm	NEW
FMR	1.30 mm	+1.30 mm	+49000.7%
IVZ Invesco	4.10 mm	+953.31 k	+30.3%
Checkpoint Capital	1.50 mm	+629.31 k	+71.9%
Portolan Capital Management	1.70 mm	+569.83 k	+50.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PHAT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jan 25	Curran Terrie	Common Stock	Sell	Dispose S	No	No	6.5877	19,109	125.88 k	360,465
21 Jan 25	Nabulsi Azmi	Common Stock	Sell	Dispose S	No	No	6.5885	7,886	51.96 k	233,390
21 Jan 25	Henderson Molly	Common Stock	Sell	Dispose S	No	No	6.5883	6,583	43.37 k	93,546
19 Dec 24	Henderson Molly	Common Stock	Sell	Dispose S	No	No	8	1,291	10.33 k	98,156
19 Dec 24	Nabulsi Azmi	Common Stock	Sell	Dispose S	No	No	8	1,118	8.94 k	239,303

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

10 Jan 25

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

12 Dec 24

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

11 Dec 24

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.

Phathom Pharmaceuticals Submits Citizen Petition To FDA Seeking Correction Of Orange Book Listings For VOQUEZNA Tablets; Phathom Believes Applicable Law Mandates A 10-Year NCE Exclusivity Period Benefitting All Vonoprazan-Based Products, With Exclusivity Until May 3, 2032

11 Dec 24

Press releases

From Benzinga Pro

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

29 Jan 25

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)